Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666089 | 1.00 | TSHR (0.62) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL12733522 | 0.94 | TSHR (0.67) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL18923980 | 0.92 | TSHR (0.56) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL18923938 | 0.92 | TSHR (0.56) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL20151931 | 0.92 | ALDH1A1 (0.55) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL12673953 | 0.92 | ALDH1A1 (0.55) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL11921661 | 0.92 | ALDH1A1 (0.55) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL26297954 | 0.91 | ALDH1A1 (0.53) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL27131417 | 0.90 | TSHR (0.61) | TSHRALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL12733524 | 0.90 | TSHR (0.76) | TSHRALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | TSHR 819/4885ALDH1A1 4181/4885HPGD 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.